Background: Central venous catheters (CVC) are a potential source of bacteraemia and have been associated with increased mortality in haemodialysis patients. We aimed to investigate the relationships between haemodialysis vascular access, taking into account changes in vascular access type during patients' lives, and cause specific mortality risk in a national cohort of dialysis patients. Methods: Prospective cohort study including all patients receiving haemodialysis in Scotland at annual cross sectional surveys in 2009, 2010 and 2011. Data were collected through the Scottish Renal Registry and by a structured review of case records following death. Cox proportional hazards regression and multivariable logistic regression were used to model survival and risk of death from septicaemia respectively.
Summary
Background: Central venous catheters (CVC) are a potential source of bacteraemia and have been associated with increased mortality in haemodialysis patients. We aimed to investigate the relationships between haemodialysis vascular access, taking into account changes in vascular access type during patients' lives, and cause specific mortality risk in a national cohort of dialysis patients. Methods: Prospective cohort study including all patients receiving haemodialysis in Scotland at annual cross sectional surveys in 2009, 2010 and 2011. Data were collected through the Scottish Renal Registry and by a structured review of case records following death. Cox proportional hazards regression and multivariable logistic regression were used to model survival and risk of death from septicaemia respectively.
Results: Of a cohort of 2666 patients, 873 (32%) died during follow-up. After case-mix adjustment, patients using only tunnelled CVC during follow-up had a higher risk of all cause mortality across all strata of prior renal replacement therapy exposure [adjusted hazard ratio (HR): 1.83-2.08]. Case-mix adjusted risks of cardiovascular death (adjusted
Introduction
Survival rates of haemodialysis patients are improving 1, 2 ; however mortality, morbidity and hospitalization rates remain high. 1, 2 The median survival of patients starting renal replacement therapy (RRT) in Scotland is only 4.1 years, 2 and the risk of death for people with stage 5 chronic kidney disease (CKD) is 14 times higher that of age matched general population. 3 Survival rates vary considerably between UKbased renal units providing RRT. 1, 2 Such variation in outcomes may be due to differences in patient case-mix such as burden of other comorbid illness, 4,5 socio-economic differences in catchment areas 6 or differences in clinical practice and processes of care between renal units. Vascular access type has been identified as one such potentially modifiable process of care. 7 The use of central venous catheters (CVCs) as dialysis access remains common and indeed is rising in many countries. 8 This is despite international 9 and national 10 guidelines identifying an arteriovenous fistula (AVF) as the preferred form of vascular access and observational evidence of worse patient outcomes with CVC use. Previous studies have demonstrated an association between the use of CVCs and higher risks of mortality [11] [12] [13] [14] [15] [16] [17] and hospitalization, 14 although in these studies, vascular access type was typically recorded only at initiation of RRT or at a single time point subsequently. In addition, the potential differences in risk between tunnelled and non-tunnelled CVCs have not been fully explored.
The aim of this study was to examine the association between all-cause and cause specific mortality with haemodialysis vascular access in a national prospective cohort of haemodialysis patients.
Methods
This is a prospective observational cohort study of all adult patients in Scotland receiving haemodialysis for established renal failure (ERF) at three annual time points (June 2009, May 2010 and May 2011). These time points correspond to the Scottish Renal Registry (SRR) census, an annual cross sectional survey of all patients receiving dialysis for ERF in Scotland. The census collects a variety of patient level data including haemodialysis vascular access in use on the census day, and data were returned for 96% of the prevalent haemodialysis population averaged across the 3 years, with no significant inter-year variation. For the survival analysis, patients were followed-up until death or until 1 May 2012; maximum follow-up was therefore 35 months. Patients receiving RRT for acute kidney injury were excluded as were patients who switched to peritoneal dialysis or renal transplantation during the follow-up period without switching back to haemodialysis. Patients who stopped RRT but who did not recover renal function (e.g. where RRT was withdrawn and end of life care commenced) were included, as were those dying within 90 days of commencing RRT for ERF.
Deaths were identified through the SRR as part of the Scottish Mortality Audit of Renal Replacement Therapy (SMARRT), a national audit instigated to investigate apparent centre-based variation in RRT outcomes. Following notification of death, data routinely collected by the SRR were augmented by data collected by nominated nephrologists in each unit. Data were either entered directly onto the SRR database via a secure connection or were recorded on a purpose designed paper form for later entry to the SRR. The augmented data included information about both the location and primary cause of death, comorbidity and vascular access in use for haemodialysis until death or withdrawal of RRT. A check of data completion was circulated regularly by the investigators to all renal units in Scotland to ensure data collection was as complete as possible. Vascular access type was classified as tunnelled CVC (TCVC), non-tunnelled CVC (NTCVC), AVF or arteriovenous graft (AVG); AVG and AVF were combined into the group 'AVG/AVF' for statistical analysis. For the primary analysis, patients were sub-classified into groups depending on whether there had been a documented change in vascular access type at any of the three annual surveys: 'TCVC only', 'AVF/AVG only' and 'TCVC and AVF/AVG'. The latter group included patients switching in the follow-up period from TCVC to AVF/AVG and vice versa. Patients documented as having a NTCVC at any point were not included in the main analysis due to small numbers. Similarly, we did not include NTCVC and TCVC in a combined 'CVC' group on the grounds that this would assume that mortality risk is the same in these two groups.
Primary causes of death and primary renal diagnosis (PRD) were coded using ERA-EDTA codes. 18 PRD codes were grouped into standard SRR diagnosis groups 18 and cause of death codes into cardiovascular, infection, dialysis complication, malignancy, withdrawal of RRT and other cause of death groups. Death due to withdrawal of RRT was classified as such where this was felt to be the proximate cause of death, although in some cases the decision to withdraw RRT was made in the setting of impending death from other causes.
Univariate analysis was carried out with Pearson 2 tests or Kruskall-Wallis tests as appropriate, using a significance level of 0.01. Kaplan-Meier plots were used to examine the association between duration of vascular access and survival. Multivariate survival analysis was carried out using a Cox proportional hazards model with evaluation of the proportional hazards assumption carried out using log-log plots for all covariates. The odds of death from septicaemia vs. any other cause were estimated using multivariable logistic regression. All models included the following categorical covariates: sex, PRD group, age group at census date and referral to start of RRT of <90 days. Analyses were stratified by three groups of RRT exposure prior to first ascertainment of vascular access type. These groups were defined as tertiles of the log-transformed RRT exposure prior to first ascertainment of vascular access type: 'Low' (0-330 days), 'Medium' (331-1479 days) and 'High' (51480 days). All incident RRT patients are therefore included in the 'Low' exposure group. A significance level of 0.05 was assigned for multivariate analysis and all analyses were carried out using SPSS (V17).
Results
The cohort included 2666 haemodialysis individuals followed-up for a total of 1.97 million days. Vascular access type was ascertained in at least one time point in 2580 (96%). During follow-up, 873 (33%) patients died, and cause of death information was available for 727 (83%). The characteristics of the cohort are presented in Table 1 . There were a greater proportion of females and a higher median age at start of RRT in the group using only TCVCs vs. those using only AVF/AVG. Patients only using AVF/ AVG had a longer RRT exposure prior to first ascertainment of vascular access type; similarly there was a larger proportion of low exposure/incident RRT patients in the TCVC only group. Most patients did not switch vascular access type during follow-up: 86% of those using only a TCVC during the study period died while still using a TCVC. Mortality rates were much higher for those only using TCVC compared with those only with an AVF/AVG: 45% vs. 28% (P < 0.0001). There were no significant differences in the prevalence of any major comorbidities at death (ischaemic heart disease, valvular heart disease, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, COPD, diabetes mellitus, malignancy, chronic liver disease) between any of the vascular access groups. Across the whole cohort, 92% of patients had been diagnosed with at least one of these comorbidities at death, with a median of 2 (IQR 1-4) major comorbidity diagnoses per patient.
Unadjusted survival was worse for patients using only TCVCs compared with only AVF/AVG for all strata of RRT exposure (Figure 1) . Similarly, the results of the Cox proportional hazards model demonstrate increased case-mix adjusted risk of mortality for patients with only TCVC use across all strata of RRT exposure (Table 2) . Mortality risk was highest in those with low prior RRT exposure, in whom those using only TCVCs had a 2.08-fold risk of mortality compared with those dialysing via only AVF/AVG. No significant differences were observed compared with patients using both AVF/AVG and TCVCs, although the small numbers of the group are reflected in the wide confidence intervals of the hazard ratio (HR) estimates. Similar estimates of HRs were obtained in a sensitivity analysis which excluded patients with <90 days of follow-up prior to initiation of RRT.
HRs for both cardiovascular and infection-related deaths were significantly higher for patients using only TCVCs. Again, risk was highest in those with low RRT exposure prior to inclusion. The distribution of cause of death differed between the groups (Table 3) : Those using TCVCs were more likely to die of infection or withdrawal of RRT than those using AVF/AVG. Conversely, a greater proportion of deaths were caused by cardiovascular events in those using only AVF/AVG. Over half (53.7%) of all the deaths from septicaemia (n = 62 in the whole cohort) occurred in patients using only TCVCs up to death, despite this group accounting for only 28% of patients. Compared with patients using only AVF/AVG, patients using only TCVCs were estimated to have 6.9-fold higher odds of dying from septicaemia vs. all other causes (Table 4) . This difference persisted in a sensitivity analysis that excluded patients with low RRT exposure (including all incident RRT patients).
Discussion
This study demonstrates strong associations between use of TCVCs for haemodialysis access and risk of death in a national cohort of haemodialysis patients. Higher risk of death with TCVC use was observed not just among incident RRT patients, but also in patients with long histories of RRT use. Similarly, by recognizing that patients may switch between vascular access types during their time on haemodialysis, this study demonstrates the risks associated with sustained TCVC use, not just vascular access type as recorded at a single time point or at the initiation of RRT. After adjusting for case-mix, TCVC use was associated with a 2.02-to 2.95-fold higher risk of cardiovascular mortality and a 3.10-to 3.63-fold higher risk of infection-related mortality than exclusive use of AVF/AVG during follow-up. Similarly, patients using only TCVCs up to death had a 6.9-fold higher odds of dying from septicaemia (vs. all other causes of death) compared with those using AVF/AVG. These data demonstrate that sustained TCVC use is a powerful marker of higher mortality risk in haemodialysis patients.
This observational study cannot prove the causal nature of these associations. One possible interpretation is that patients with a worse prognosis are more likely to have a TCVC because of the difficulties of establishing or sustaining a functioning AVF or AVG. Previous studies have demonstrated a number of risk factors for CVC use, including cardiac comorbidity, late referral and low baseline albumin, 12, [19] [20] [21] [22] all of which are themselves linked to higher mortality. In our study, TCVC use was similarly associated with a number of factors linked to increased mortality risk, including older age and greater use of TCVCs in the time soon after initiating RRT when mortality risk is known to be particularly high. 23 In addition, we did not demonstrate any differential mortality risk between patients with only AVF/AVG use and those who used TCVCs temporarily (switching from AVF/AVG to TCVC or vice versa), although the confidence intervals for mortality estimates were wide for this group of patients and the study may have been underpowered to detect a significant difference for the relatively small number of patients in this group.
However, studies in a variety of haemodialysis populations have consistently demonstrated higher mortality risk with CVC use, leading many to conclude that CVCs are contributing to excess mortality in haemodialysis patients. 8 CVCs are a cause of bacteraemia, with up to 3-fold higher risk of bacteraemia compared to AVFs and an incidence of catheter-related bacteraemia of 1-5 episodes per 1000 catheter days. 24 Excess cardiovascular mortality may be a consequence of the inflammatory burden of chronic or repeated bacteraemia. 25 This study is consistent with previous estimates of mortality risk associated with CVC use: HRs range from 1.4 to 2.7, 11-17 depending on methodology and cohort. This study adds to these previous estimates in a number of important ways: We have demonstrated higher risk associated with sustained TCVC use, not just TCVC use as measured at initiation of RRT or another single time point and also, in contrast with most previous studies, have distinguished TCVC from NTCVC use. By stratifying the analysis by RRT exposure, this study demonstrates that TCVCs are associated with higher mortality not only in those newly started on haemodialysis but also in those surviving to be in receipt of long-term RRT. Although this study includes more detailed vascular access data than most previous studies on this topic, it remains limited by a lack of longitudinal individual vascular access histories and relies on cross-sectional census results. We have therefore based our analyses on the assumption that no changes in vascular access type occurred between the census time points in this study.
Minimizing healthcare-associated infection has been the subject of quality improvement initiatives in many healthcare economies, including the NHS in Scotland, where the Scottish Patient Safety Programme has been implemented to address this as part of a broader focus on patient safety. 26 At the same time, there have been several high profile initiatives addressing vascular access, including the Fistula First initiative in the USA and Canada, 27 and the introduction of a mandatory best practice tariff for haemodialysis in England that provides a financial incentive for the use of AVF or AVG to haemodialysis providers. 28 Reducing the use of CVCs is, however, challenging, and at present, only a minority of renal units in the UK are reaching the target of 85% AVF/AVG prevalence recommended in clinical guidelines. 10 Construction of an AVF or AVG is impossible or too risky in some patients and there may be cultural, resource, logistic and educational barriers to reducing CVC use. Moreover, AVF formation and use are not without important side effects, such as vascular complications and haemorrhage. 29 Further efforts to characterize these barriers and identify effective strategies to increase the use of AVFs in both incident and prevalent dialysis patients should be a priority.
This study confirms and extends previous observational studies describing associations between vascular access type and mortality risk. Although a randomized controlled trial would help settle the question of whether TCVC use is a cause or merely a marker of higher mortality risk, such a trial is very unlikely to be deemed ethical. In the meantime, observational studies such as this suggest that minimizing the use of CVCs, and improving their safety profile where they are unavoidable, should be considered a high priority in efforts to improve haemodialysis outcomes.
